Maravai LifeSciences (MRVI) Stock Price, News & Analysis

Company Overview

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows. The company’s TriLink® division supplies custom nucleic acids and enzymatic reagents for RNA and DNA synthesis, while its SeraCode™ and ExoScale™ offerings provide specialized tools for protein quantification and extracellular vesicle analysis. Maravai also offers contract development and manufacturing services to support scale-up and commercialization efforts for novel biologic candidates.

Founded in 2015 and headquartered in San Diego, California, Maravai has grown through strategic acquisitions and organic innovation to serve clients in North America, Europe and Asia. The company partners with leading pharmaceutical and biotechnology organizations to advance vaccine programs, cell and gene therapies and precision diagnostics. Under the leadership of President and Chief Executive Officer Brent P. Saunders, Maravai continues to invest in research and development, expanding its global manufacturing footprint and strengthening its position in high-growth markets for advanced therapies.

Key Stats

• Today's Range: $3.81 to $3.96
• 50-Day Range: $2.83 to $3.94
• 52-Week Range: $1.95 to $4.11
• Volume: 3.56 million shs
• Average Volume: 1.74 million shs
• Market Capitalization: $1.01 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.38
• Consensus Rating: Hold

Maravai LifeSciences Stock Analysis - MarketRank™

Maravai LifeSciences scored higher than 47% of companies evaluated by MarketBeat, and ranked 522nd out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Maravai LifeSciences has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Maravai LifeSciences has a consensus price target of $5.38, representing about 36.4% upside from its current price of $3.94.

Amount of Analyst Coverage

Maravai LifeSciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Maravai LifeSciences are expected to grow in the coming year, from ($0.26) to ($0.24) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Maravai LifeSciences is -4.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Maravai LifeSciences is -4.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Maravai LifeSciences has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.67% of the float of Maravai LifeSciences has been sold short.

Short Interest Ratio / Days to Cover

Maravai LifeSciences has a short interest ratio ("days to cover") of 4.85.

Change versus previous month

Short interest in Maravai LifeSciences has recently decreased by 2.80%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Maravai LifeSciences does not currently pay a dividend.

Dividend Growth

Maravai LifeSciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.57

News Sentiment

Maravai LifeSciences has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Maravai LifeSciences this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for MRVI on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

2 people have added Maravai LifeSciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Maravai LifeSciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.49% of the stock of Maravai LifeSciences is held by insiders.

Percentage Held by Institutions

50.25% of the stock of Maravai LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MRVI Stock Analysis - Frequently Asked Questions

How have MRVI shares performed this year?

Maravai LifeSciences' stock was trading at $3.25 at the beginning of the year. Since then, MRVI shares have increased by 21.2% and is now trading at $3.94.

How were Maravai LifeSciences' earnings last quarter?

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) released its earnings results on Wednesday, February, 25th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.03. The firm earned $49.87 million during the quarter, compared to analyst estimates of $49.06 million. Maravai LifeSciences had a negative trailing twelve-month return on equity of 22.79% and a negative net margin of 70.40%.
Read the conference call transcript.

When did Maravai LifeSciences IPO?

Maravai LifeSciences (MRVI) raised $1.5 billion in an initial public offering on Thursday, November 19th 2020. The company issued 60,000,000 shares at a price of $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs acted as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers.

Who are Maravai LifeSciences' major shareholders?

Top institutional investors of Maravai LifeSciences include General American Investors Co. Inc. (0.67%), Brummer Multi Strategy AB (0.30%), Bank of New York Mellon Corp (0.13%) and Capricorn Fund Managers Ltd (0.13%). Insiders that own company stock include Gtcr Investment Xi Llc, Bernd Brust, Carl Hull, Kurt Oreshack and Gregory T Lucier.
View institutional ownership trends.

How do I buy shares of Maravai LifeSciences?

Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Maravai LifeSciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Maravai LifeSciences investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 2/25/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MRVI
• CIK: 1823239
• Web: www.maravai.com
• Phone: 858-546-0004
• Fax: N/A
• Employees: 610
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Maravai LifeSciences: $5.38
• High Price Target: $10.00
• Low Price Target: $2.00
• Potential Upside/Downside: +36.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$130.77 million
• Net Margins: -70.40%
• Pretax Margin: -126.50%
• Return on Equity: -22.79%
• Return on Assets: -11.82%

Debt

• Debt-to-Equity Ratio: 0.85
• Current Ratio: 6.60
• Quick Ratio: 5.69

Sales & Book Value

• Annual Sales: $185.74 million
• Price / Sales: 5.45
• Cash Flow: $0.43 per share
• Price / Cash Flow: 9.20
• Book Value: $1.46 per share
• Price / Book: 2.70

Miscellaneous

• Outstanding Shares: 257,070,000
• Free Float: 250,666,000
• Market Cap: $1.01 billion
• Optionable: Optionable
• Beta: 0.62